Kyrie Irving says he is moving, working out and playing with no restriction of movement. That matters because the Mavericks are still trying to answer the same question they were asking when he tore his left ACL on March 3, 2025: how close can he get back to the player who once made every possession feel like a scoring chance?
The recovery window has been long — 19 months — and the uncertainty around it is what keeps Irving from being just a health update. It is also a valuation problem. If a team believes he can return to form, how much should that belief cost?
That question is hanging over Houston, which has been linked to Irving in trade rumors. One proposed deal would send Fred VanVleet, Clint Capela and the Rockets’ 2028 first-round pick, top five protected, to Dallas. That is the kind of package that forces a team to decide whether it is buying a star or paying for the memory of one.
He is 34 now, and his career has already included more than 300 missed games because of injury, rest and personal/team protocol reasons. That history does not erase the upside, but it does explain why any trade discussion around him quickly turns from basketball fit to cost control.
The Mavericks’ season opens Oct. 21 against the Rockets, which gives the matchup a built-in reminder of how intertwined the two sides are in this conversation. Dallas is preparing for a season in which Irving is expected to be active for the 2026-27 opener on Oct. 21, 2026, with no current restrictions. He was also listed as active on Sept. 26 because of his recovery from the left ACL tear.
That is the tension for Houston and any other team watching the market: Irving’s health update is encouraging, but it does not answer the harder question. The Rockets should be interested at the right price. The challenge is deciding where that price stops being a bet on Kyrie Irving and starts becoming an overpay.